Kv1.3 Targeting Delivers Relief in the Mice Model Suffering from Lupus Nephritis

Kv1.3 Targeting Delivers Relief in the Mice Model Suffering from Lupus Nephritis

Release Date: 08-Nov-2020



In the present era, auto-immune diseases are becoming one of the highest diagnosed disease cases in the world and among all the auto-immune diseases, Lupus nephritis is considered to be responsible for taking the lives of millions of patients. Also, the association of the disease with limited therapies is also leading to increased in demand of efficient therapies. It is witnessed that the disease development and progression lead to infiltration of memory T lymphocytes in the kidney and finally leading to the damage of the organ.

 

As per analysis conducted, it has been found that lupus nephritis, diabetic nephropathy, and healthy donor kidney biopsies that there is high infiltration of active CD8+ Tm cells expressing high voltage-dependent Kv1.3 potassium channelsandmdash;key T cell function regulators. Also, the nanoparticles that were used led to down-regulation of CD40L and interferon-andgamma; (IFNandgamma;) in Tm cells from LN patients in vitro conditions. By grafting peripheral blood mononuclear cells from the patients suffering from lupus nephritis, Kv1.3-NPs were tested in humanized LN mice.

 

Some of the features that were exhibited by the mice model suffering from lupus nephritis mice were: reduced survival versus healthy donor PBMC engrafted mice as well as ncreased IFNandgamma; and CD3+CD8+ T cell renal infiltration. To conclude, it was stated that Kv1.3-NP treatment of patient PBMCs before engraftment decreased CD40L/IFNandgamma; and prolonged survival of LN mice. Therefore, concluding that there are number of potential benefits when targeted Kv1.3 in the mice model suffering from lupus nephritis.

Need custom market research solution? We can help you with that too.